<i>N</i>-Aryl-2-aminobenzimidazoles: Novel, Efficacious, Antimalarial Lead Compounds
作者:Sreekanth Ramachandran、Shahul Hameed P.、Abhishek Srivastava、Gajanan Shanbhag、Sapna Morayya、Nikhil Rautela、Disha Awasthy、Stefan Kavanagh、Sowmya Bharath、Jitendar Reddy、Vijender Panduga、K. R. Prabhakar、Ramanatha Saralaya、Robert Nanduri、Anandkumar Raichurkar、Sreenivasaiah Menasinakai、Vijayashree Achar、María Belén Jiménez-Díaz、María Santos Martínez、Iñigo Angulo-Barturen、Santiago Ferrer、Laura María Sanz、Francisco Javier Gamo、Sandra Duffy、Vicky M. Avery、David Waterson、Marcus C. S. Lee、Olivia Coburn-Flynn、David A. Fidock、Pravin S. Iyer、Shridhar Narayanan、Vinayak Hosagrahara、Vasan K. Sambandamurthy
DOI:10.1021/jm500715u
日期:2014.8.14
malaria. This compound displayed an excellent pharmacokinetic profile with a long half-life (19 h) in rat blood. This profile led to an extended survival of animals for over 30 days following a dose of 50 mg/kg in the Pb malaria model. Compound 12 retains its potency against a panel of Pf isolates with known mechanisms of resistance. The fast killing observed in the in vitro parasite reduction ratio (PRR)
从阿斯利康公司化合物集合的表型筛选中,N-芳基-2-氨基苯并咪唑类化合物已成为对抗恶性疟原虫(Pf)无性血液阶段的新命中。药物化学对Pf和ADME性质的效力进行了优化,从而确定了12种为先导分子。化合物12在疟疾的伯氏疟原虫(Pb)模型中有效。该化合物在大鼠血液中显示出出色的药代动力学特征,具有长的半衰期(19小时)。在Pb剂量为50 mg / kg时,此特征导致动物延长了30天以上的生存期疟疾模型。化合物12保持其对具有已知抗性机制的Pf分离物组的效力。在体外寄生虫减少率(PRR)分析中观察到的快速杀灭作用与延长的生存期一起突显了这种新颖的化学类别用于治疗疟疾的希望。